| Identification | Back Directory | [Name]
CP-456773 sodium | [CAS]
256373-96-3 | [Synonyms]
CPD1600
Crid3 sodium
MCC950 sodium
CP-456773 sodium
MCC950(CP-456773)
CRID3 sodium salt
MCC 950 sodium NEW
MCC950 sodium salt
CP-456773 sodium salt
MCC-950 Sodium, CP-456773
MCC950 (CP-456773) sodium
MCC950 Sodium Salt (CP-456773)
MCC950 sodium (CP-456773 sodium
CP-456773 sodium salt >=98% (HPLC)
CP-456773 SODIUM; CRID3 SODIUM SALT; MCC-950 SODIUM; CP456773 SODIUM; CRID-3 SODIUM SALT
sodium salt of 1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea
N-[[(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide sodium salt
N-[[(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide monosodium salt | [Molecular Formula]
C20H23N2NaO5S | [MDL Number]
MFCD28580120 | [MOL File]
256373-96-3.mol | [Molecular Weight]
426.462 |
| Chemical Properties | Back Directory | [storage temp. ]
room temp | [solubility ]
Soluble in DMSO:50.0(Max Conc. mg/mL);117.24(Max Conc. mM)
Water:30.0(Max Conc. mg/mL);70.35(Max Conc. mM) | [form ]
powder | [color ]
white to beige | [Water Solubility ]
water: 1mg/mL
DMSO: 50mg/mL |
| Hazard Information | Back Directory | [Uses]
CP-456773 sodium salt has been used :
- In in vivo experiments to study the neuroprotective action of ketogenic diet.
- To study the effect of inhibition of NLRP3 (nod-like receptor protein 3) inflammasome activity on tumor progression in mouse models.
- To study the cholesterol crystal-mediated IL-1b (interleukin-1b) response in placental explants.
| [Biochem/physiol Actions]
CP-456773 is known to inhibit the release of other proinflammatory cytokines such as IL-1α and IL-18. It is also referred to as MCC950. | [in vivo]
MCC950 reduces Interleukin-1p (IL-1β) production and attenuates the severity of experimental autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis. Pre-treatment with MCC950 reduces serum concentrations of IL-1β and IL-6 while it does not considerably decrease the amount of TNF-α. Treatment of mice with MCC950 delays the onset and reduced the severity of EAE. Intracellular cytokine staining and FACS analysis of brain mononuclear cells from mice sacrificed on day 22 shows modestly reduced frequencies of IL-17 and IFN-γ producing CD3+ T cells in MCC950 treated mice in comparison with PBS-treated mice. IFN-γ and particularly IL-17 producing cell numbers are also reduced in both the CD4+ and γδ+ sub-populations of CD3+ T cells[1]. | [IC 50]
NLRP3 | [storage]
+4°C |
|
|